$INSY to Present at RBC Capital Markets 2016 Global Healthcare Conference

The presentation will be webcast live athttps://www.veracast.com/webcasts/rbc/healthcare2016/32202255515.cfm at the aforementioned time as well as archived for 90 days thereafter on the Company’s website atwww.insysrx.com, under the Investors Section.

About Insys Therapeutics, Inc.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product: Subsys^® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Syndros® (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.

Subsys^® and Syndros® are registered trademarks of Insys Therapeutics, Inc.

Investor Contact:
Lisa M. Wilson, President
In-Site Communications, Inc.
Phone: 212-452-2793
Email: lwilson@insitecony.com